IC-GREEN- indocyanine green kit

IC-Green by

Drug Labeling and Warnings

IC-Green by is a Prescription medication manufactured, distributed, or labeled by Renew Pharmaceuticals Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion

    IC-GREEN is indicated for fluorescence imaging of vessels (micro- and macro- vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients aged 1 month and older.

    1.2 Visualization of Extrahepatic Biliary Ducts

    IC-GREEN is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older.

    1.3 Lymphatic Mapping of Cervical and Uterine Cancer

    IC-GREEN is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management.

    1.4 Ophthalmic Angiography

    IC-GREEN is indicated for use in ophthalmic angiography in adults and pediatric patients.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dose, Administration and Imaging for Visualization of Vessels, Blood Flow and Tissue Perfusion

    Dosing

    Adults:

    The recommended dose of IC-GREEN for a single image sequence for visualization of vessels, blood flow and tissue perfusion in adults is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution.

    For visualization of perfusion in extremities through the skin in adults, the recommended dose is 3.75 mg to 10 mg administered intravenously as 1.5 mL to 4 mL of a 2.5 mg/mL solution.

    Immediately flush with a 10 mL bolus of 0.9% Sodium Chloride Injection.

    Pediatric patients aged 1 month and older:

    The recommended dose of IC-GREEN for a single image sequence for visualization of vessels, blood flow and tissue perfusion in pediatric patients aged 1 month and older is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution. Lower doses may be administered in younger patients and in those with lower body weight. Adjust the amount and type of flush to avoid volume and/or sodium overload.

    In both adults and pediatric patients aged 1 month and older, additional doses may be administered to obtain imaging sequences during the procedure. Do not exceed the maximum total dose of 2 mg/kg.

    Administration

    Prior to the imaging procedure, draw up the desired dose of IC-GREEN solution into appropriate syringes and prepare a 10 mL syringe of 0.9% Sodium Chloride Injection.

    Administer via a central or peripheral venous line using a three-way stopcock attached to an injection port on the infusion line. Inject the prepared IC-GREEN into the line as a tight bolus. Immediately switch the access on the stopcock and inject the prepared flush.

    Imaging Instructions

    IC-GREEN may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of vessels, blood flow and tissue perfusion.

    A fluorescence response should be visible in blood vessels within 5 seconds to 15 seconds after injection.

    2.2 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts

    Dosing and Administration

    The recommended dose of IC-GREEN for visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older is 2.5 mg administered intravenously as 1 mL of a 2.5 mg/mL solution at least 45 minutes prior to surgery.

    Additional doses may be administered to obtain imaging sequences during the procedure.

    Do not exceed a total dose of 2 mg/kg.

    Imaging Instructions

    IC-GREEN may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of extrahepatic biliary ducts.

    Fluorescence is visible in the biliary tree within 45 minutes after injection.

    2.3 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer

    Dosing and Administration

    The recommended dose of IC-GREEN for lymphatic mapping of cervical and uterine cancer in adults is 5 mg administered interstitially as four 1 mL injections of a 1.25 mg/mL solution into the cervix, at the 3 o’ clock and the 9 o’clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.

    Imaging Instructions

    IC-GREEN may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping of cervical and uterine cancer.

    Fluorescent lymphatic vessels and lymph nodes should begin to be visible within 1 minute after injection.

    2.4 Recommended Dose and Administration for Ophthalmic Angiography

    Dosing and Administration

    Doses up to 40 mg IC-GREEN in 2 mL of Sterile Water for Injection depending on the imaging equipment and technique used should be administered intravenously and immediately followed by a 5 mL bolus of 0.9% Sodium Chloride Injection. The antecubital vein can be used for IC-GREEN administration.

    2.5 Reconstitution Instructions

    General

    • Prepare IC-GREEN using aseptic techniques prior to procedure.
    • Inspect the reconstituted solution for particulate matter. The reconstituted solution should be a clear, green solution.
    • Use the prepared solution within 6 hours.
    • Discard any unused product.

    Visualization of Vessels, Blood Flow, Tissue Perfusion and Extrahepatic Biliary Ducts

    Dissolve 25 mg of IC-GREEN with 10 mL Sterile Water for Injection to form a concentration of 2.5 mg/mL indocyanine green.

    Lymphatic Mapping of Cervical and Uterine Cancer

    Dissolve 25 mg of IC-GREEN with 20 mL Sterile Water for Injection to form a concentration of 1.25 mg/mL indocyanine green.

    Ophthalmic Angiography

    Dissolve doses up to 40 mg of IC-GREEN with 2 mL Sterile Water for Injection.

  • 3 DOSAGE FORMS AND STRENGTHS

    For injection: 25 mg of indocyanine green as a sterile, lyophilized, green powder for reconstitution provided in a 25 mL single-patient-use vial.

  • 4 CONTRAINDICATIONS

    IC-GREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Hypersensitivity reactions including anaphylaxis, urticaria and deaths due to anaphylaxis have been reported following intravenous administration of IC-GREEN [see Adverse Reactions (6)].

    IC-GREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green [see Contraindications (4)]. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

    5.2 Interference with Thyroid Radioactive Iodine Uptake Studies

    Because IC-GREEN contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration [see Drug Interactions (7)].

  • 6 ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in the labeling:

    • Hypersensitivity Reactions [see Warnings and Precautions (5.1)].

    The following adverse reactions have been identified during post-approval use of IC-GREEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Immune System Disorders: Anaphylaxis, urticaria

  • 7 DRUG INTERACTIONS

    Interference with Thyroid Radioactive Iodine Uptake Studies

    Because IC-GREEN contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of IC-GREEN.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no adequate and well-controlled studies of IC-GREEN in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green.

    All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    8.2 Lactation

    Risk Summary

    Seventeen cases of indocyanine green use in lactating women have been reported in the scientific literature with no adverse events observed in the breastfed infant. However, there are no data on the presence of indocyanine green in human milk or the effects on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for IC-GREEN and any potential adverse effects on the breastfed infant from IC-GREEN or from the underlying maternal condition.

    8.4 Pediatric Use

    Use of IC-GREEN for visualization of vessels, blood flow and tissue perfusion has been established in pediatric patients aged 1 month and older. Pediatric use is supported by published data in 49 pediatric patients who received indocyanine green for assessment of blood flow and tissue perfusion in cardiovascular, vascular, and plastic, micro- and reconstructive surgical procedures, and by clinical trials in adults. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration (2.1)]. The use of IC-GREEN for visualization of vessels, blood flow and tissue perfusion has not been established in pediatric patients aged less than 1 month.

    Use of IC-GREEN for visualization of extrahepatic biliary ducts has been established in pediatric patients aged 12 years and older. Pediatric use is supported by clinical trials in adults in addition to clinical use in pediatric patients. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration (2.2)]. The use of IC-GREEN for visualization of extrahepatic biliary ducts has not been established in pediatric patients aged less than 12 years.

    Use of IC-GREEN for visualization of lymph nodes and lymphatic vessels during lymphatic mapping for cervical and uterine cancer have not been established in pediatric patients.

    Use of IC-GREEN for ophthalmic angiography has been established in pediatric patients. Pediatric use is supported by evidence from the published literature.

    8.5 Geriatric Use

    Of the total number of patients in clinical studies of indocyanine green for injection for visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of patients in clinical studies of indocyanine green for injection for visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over. Clinical studies of indocyanine green for injection for visualization of extrahepatic biliary ducts did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

    No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

  • 11 DESCRIPTION

    IC-GREEN (indocyanine green for injection) is an optical imaging agent for intravenous or interstitial use.

    Each vial contains 25 mg of indocyanine green with not more than 5% sodium iodide as a sterile, lyophilized, green powder. IC-GREEN has a pH of 5.5-7.5 when reconstituted with Sterile Water for Injection, USP.

    The chemical name for Indocyanine Green is 1 HBenz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4- sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt.

    Molecular Formula: C43H47N2NaO6S2; Molecular Mass: 774.96 g/mol, with the following structural formula:

    Structural Formula

    Indocyanine green has a peak spectral absorption at 805 nm in blood.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and macro-vasculature, blood flow and tissue perfusion, the extrahepatic biliary ducts, and for lymphatic mapping of lymph nodes and lymphatic vessels.

    12.2 Pharmacodynamics

    There are no pharmacodynamic data.

    12.3 Pharmacokinetics

    Distribution

    Following intravenous injection, indocyanine green binds to plasma proteins (98%) and is largely confined to the intravascular compartment. Indocyanine green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin.

    Following interstitial injection, indocyanine green binds to proteins in lymph fluid and the interstitial space, is taken up by the lymphatic vessels, and drains to the lymph nodes.

    Since excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature, IC-GREEN is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera.

    Elimination

    Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    No studies have been performed to evaluate the potential for carcinogenicity, mutagenicity, or impairment of fertility by indocyanine green.

  • 14 CLINICAL STUDIES

    14.1 Lymphatic Mapping of Cervical and Uterine Cancer

    The effectiveness of IC-GREEN for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer has been established based on a study of another formulation of indocyanine green for injection. Below is a description of the FILM Study (NCT 02209532).

    The study was a randomized, prospective, multi-center, open-label study in patients with early stage uterine or cervical cancer and no known regional nodal or metastatic disease by standard clinical evaluation. Indocyanine green and a blue dye comparator were injected into the cervix of patients at the beginning of the operative procedure.

    A total of 176 patients were randomized to receive either indocyanine green followed by blue dye or blue dye followed by indocyanine green. A total of four 1 mL injections of a 1.25 mg/ml solution of indocyanine green for a total dose of 5 mg were administered interstitially into the cervix at the 3 o'clock and 9 o'clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.

    Lymphatic mapping was performed intraoperatively using a fluorescence imaging device and standard light, followed by excision of tissues identified by indocyanine green, blue dye, or the surgeon's visual and palpation examination. The resected tissues were evaluated by histopathology to confirm presence of lymph nodes. The efficacy of indocyanine green in the detection of lymphatic vessels and lymph nodes during lymphatic mapping procedures was determined by the number of histology-confirmed lymph nodes detected by indocyanine green and/or the blue dye comparator.

    The mean age of the 176 patients was 63 years (range: 31 to 88 years); distribution by race and ethnicity was 79% White, 4% Black or African American, 3% Asian, 13% Hispanic/Latino and 1% other.

    Table 1 shows the distribution of resected, confirmed lymph nodes detected by indocyanine green or blue dye in the modified intent-to-treat population (mlTT). Among the confirmed lymph nodes identified, 93% were identified using indocyanine green, and 43% were identified using blue dye, a difference of 50% [95% confidence interval 39% to 60%].

    Table 1: Distribution of Resected, Confirmed Lymph Nodes Detected by Indocyanine Green or Blue Dye (BD)

    Analysis Population

    Nodes (n)

    All Lymph Nodes Detected with Indocyanine Green

    All Lymph Nodes Detected with BD

    Lymph Nodes Detected with Indocyanine Green Only

    Lymph Nodes Detected with BD Only

    Lymph Nodes Detected with Neither

    mlTT

    513

    (476/513)
    93%

    (220/513)
    43%

    (262/513)
    51%

    (6/513)
    1%

    (31/513)
    6%

    Table 2 shows the number of patients with at least one resected, confirmed lymph node and the number of patients with at least one bilateral lymph node pair detected by indocyanine green or blue dye. With indocyanine green, approximately 97% of patients had at least one resected, confirmed lymph node detected and 73% had at least one bilateral lymph node pair detected, compared with 68% and 28%, respectively, with blue dye (p-values for each analysis <0.0001).

    Table 2: Distribution of Patients with at Least One Confirmed Unilateral Lymph Node/ Bilateral Pair Detected by Indocyanine Green or Blue Dye (BD)
    *: patients with at least one resected confirmed lymph node detected unilaterally
    **: patients with at least one resected confirmed lymph node detected bilaterally

    Analysis Population

    Patients (n)

    Patients with All Lymph Nodes Detected with Indocyanine Green

    Patients with All Lymph Nodes Detected with BD

    Patients with Lymph Nodes Detected with Indocyanine Green only

    Patients with Lymph Nodes Detected with BD only

    Patients with Lymph Nodes Detected with Neither

    mlTT Unilateral*

    172

    (167/172)
    97%

    (118/172)
    68%

    (51/172)
    30%

    (2/172)
    1%

    (3/172)
    3%

    mlTT Bilateral**

    (126/172)
    73%

    (49/172)
    28%

    (79/172)
    46%

    (2/172)
    1%

    (44/172)
    26%
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    IC-GREEN (indocyanine green for injection) is supplied as a kit (NDC: 70100-825-02) containing the following:

    • Six 25 mL single-patient-use vials of IC-GREEN (25 mg each) as a sterile, lyophilized green powder for reconstitution NDC: 70100-725-01
    • Six single-dose vials of Sterile Water for Injection (10 mL each) NDC: 63323-185-10 or NDC: 0409-4887-17

    Storage and Handling

    Store at 20°C to 25°C (68°F to 77°F).

  • 17 PATIENT COUNSELING INFORMATION

    Hypersensitivity Reactions

    Advise patients to seek medical attention for reactions following injection of IC-GREEN such as difficulty breathing, swollen tongue or throat, skin reactions including hives, itching and flushed or pale skin, low blood pressure, a weak and rapid pulse and other symptoms or signs of an anaphylactic reaction [see Warnings and Precautions (5.1)].

  •  

    Manufactured by:
    Patheon Italia S.p.A.
    20900 Monza (MB), ITALY

    Distributed by:
    Diagnostic Green LLC
    Farmington Hills, Ml 48331

    Sterile Water for injection, USP is manufactured by:
    Fresenius Kabi USA, LLC
    Grand Island, NY 14072

    or

    Hospira, Inc.
    Rocky Mount, NC 27804

    51047

  • PRINCIPAL DISPLAY PANEL - Vial

    Principal Display Panel - Vial

    Vial Label

    NDC: 70100-725-01          Rx only    Sterile

    IC-GREEN®
    (indocyanine green
    for injection)

    25 mg/Vial

    Single-Patient-Use
    For Intravenous or Interstitial Use
    After reconstitution, use within 6 hours.

    Distributed by: Diagnostic Green LLC

    51045          12/2024

    Lot No.
    Exp.:

  • PRINCIPAL DISPLAY PANEL – Sterile Water Vial

    Principal Display Panel - Sterile Water Vial

    Sterile Water Label

    10 mL   Single-dose

    Sterile Water
    for Injection, USP

    FOR DRUG DILUENT USE

    Rx only               NDC: 0409-4887-17

    Contains no antimicrobial or other added
    substance.     Sterile, nonpyrogenic. Do not give
    intravenously unless rendered nearly isotonic.

    Hospira, Inc.              RL-4428
    Lake Forest, IL 60045 USA

  • PRINCIPAL DISPLAY PANEL - Carton

    Principal Display Panel - Carton

    Carton Label

    NDC: 70100-825-02          Rx Only - Sterile

    IC-GREEN®
    (indocyanine green for injection)

    25 mg/Vial

    Single-Patient-Use     For Intravenous or Interstitial Use

    Distributed by: Diagnostic Green LLC

    Back Panel

    NDC: 70100-825-02           Rx Only - Sterile

    Recommended Dosage and Reconstitution
    Instructions: See Prescribing Information
    Use within 6 hours after reconsituition.

    STORAGE: Store at 20° to 25° C (68° to 77°F)
    KIT CONTAINS:
     Six vials of IC-GREEN (25 mg each)
    Six Sterile Water for Injection (10 mL each)

    IC-GREEN®
    (indocyanine green for injection)

    25 mg/Vial

    Single-Patient-Use     For Intravenous or Interstitial Use

    Side Panel

    IC-GREEN®
    (indocyanine green for injection)

    Distributed by:
    Diagnostic Green LLC
    Farmington Hills MI 48331 USA

    Manufactured by:
    Patheon Italia S.p.A.
    20052 Monza (Milano) ITALY

    Sterile Water Manufactured by:
    Hospira, Inc.
    Rocky Mount, NC 27804
    or
    Fresenius Kabi USA, LLC
    Grand Island, NY 14072

    12/2024

  • INGREDIENTS AND APPEARANCE
    IC-GREEN 
    indocyanine green kit
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70100-825
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70100-825-026 in 1 CARTON04/15/2025
    11 in 1 PACKAGE; Type 0: Not a Combination Product
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL 1 
    Part 21 VIAL, PLASTIC 10 mL
    Part 1 of 2
    IC-GREEN 
    indocyanine green injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source)NDC: 70100-725
    Route of AdministrationINTRAVENOUS, INTERSTITIAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    INDOCYANINE GREEN (UNII: IX6J1063HV) (INDOCYANINE GREEN ACID FORM - UNII:C4V974V932) INDOCYANINE GREEN25 mg
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    NITROGEN (UNII: N762921K75)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70100-725-011 in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01152504/15/2025
    Part 2 of 2
    STERILE WATER 
    water injection
    Product Information
    Item Code (Source)NDC: 0409-4887
    Route of AdministrationINTRAVENOUS, INTERSTITIAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    WATER (UNII: 059QF0KO0R) (WATER - UNII:059QF0KO0R) WATER1 mL  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0409-4887-1710 mL in 1 VIAL, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01880110/27/1982
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01152504/15/2025
    Labeler - Renew Pharmaceuticals Limited (985716301)

    • Trademark Results [IC-Green]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    IC-GREEN
    IC-GREEN
    75315149 2189196 Live/Registered
    Akorn, Inc.
    1997-06-26
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.